Metabolic Myopathies

  • Alan N. Baer


  • The metabolic myopathies are a heterogeneous group of diseases characterized by impaired skeletal muscle energy production.

  • Primary metabolic myopathies are associated with genetic defects in glycogen and lipid metabolism.

  • Secondary types occur with abnormal production of parathyroid, thyroid, and cortisol production and vitamin D defi ciency.

  • ■ Symptoms occur mainly during or shortly after exercise and include pain, weakness, and cramping, and can result in myoglobinuria due to muscle necrosis.


Serum Creatine Kinase Mitochondrial Myopathy Carnitine Level Metabolic Myopathy Acid Maltase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vladutiu GD. The molecular diagnosis of metabolic myopathies. Neurol Clin 2000;18:53–104.PubMedCrossRefGoogle Scholar
  2. 2.
    DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001;24:984–999.PubMedCrossRefGoogle Scholar
  3. 3.
    Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N Engl J Med 2003;349:2503–2509.PubMedCrossRefGoogle Scholar
  4. 4.
    Livingstone C, Chinnery PF, Turnbull DM. The ischaemic lactateammonia test. Ann Clin Biochem 2001;38:304–310.PubMedCrossRefGoogle Scholar
  5. 5.
    Wortmann RL, DiMauro S. Differentiating idiopathic inflammatory myopathies from metabolic myopathies. Rheum Dis Clin North Am 2002;28:759–778.PubMedCrossRefGoogle Scholar
  6. 6.
    Greenberg SA, Walsh RJ. Molecular diagnosis of inheritable neuromuscular disorders. Part II: application of genetic testing in neuromuscular disease. Muscle Nerve 2005;31:431–451.PubMedCrossRefGoogle Scholar
  7. 7.
    Kiechl S, Kohlendorfer U, Thaler C, et al. Different clinical aspects of debrancher defi ciency myopathy. J Neurol Neurosurg Psychiatry 1999;67:364–368.PubMedCrossRefGoogle Scholar
  8. 8.
    Amato AA. Acid maltase defi ciency and related myopathies. Neurol Clin 2000;18:151–165.PubMedCrossRefGoogle Scholar
  9. 9.
    Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of nonclassic Pompe’s disease; a review of 225 published cases. J Neurol 2005;252:875–884.PubMedCrossRefGoogle Scholar
  10. 10.
    Haller RG, Lewis SF. Glucoseinduced exertional fatigue in muscle phosphofructokinase defi ciency. N Engl J Med 1991;324:364–369.PubMedCrossRefGoogle Scholar
  11. 11.
    Wang Y, Ye J, Ganapathy V, Longo N. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine defi ciency. Proc Natl Acad Sci USA 1999;96: 2356–2360.PubMedCrossRefGoogle Scholar
  12. 12.
    Cwik VA. Disorders of lipid metabolism in skeletal muscle. Neurol Clin 2000;18:167–184.PubMedCrossRefGoogle Scholar
  13. 13.
    Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II defi ciency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005;62:37–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Olpin SE. Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. Clin Lab 2005; 51:289–306.PubMedGoogle Scholar
  15. 15.
    DiMauro S, Schon EA. Mitochondrial respiratorychain diseases. N Engl J Med 2003;348:2656–2668.PubMedCrossRefGoogle Scholar
  16. 16.
    Nardin RA, Johns DR. Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve 2001;24:170–191.PubMedCrossRefGoogle Scholar
  17. 17.
    Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 2003;126:413–423.PubMedCrossRefGoogle Scholar
  18. 18.
    Tarnopolsky MA, Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports Exerc 2005;37:2086–2093.PubMedCrossRefGoogle Scholar
  19. 19.
    Taylor RW, Schaefer AM, Barron MJ, McFarland R, Turnbull DM. The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004;14:237–245.PubMedCrossRefGoogle Scholar
  20. 20.
    Tarnopolsky MA, Parise G, Gibala MJ, Graham TE, Rush JW. Myoadenylate deaminase defi ciency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol 2001;533:881–889.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Alan N. Baer
    • 1
  1. 1.Department of Medicine, Chief, Section of RheumatologyUniversity at Buffalo, State University of New YorkBuffaloUSA

Personalised recommendations